Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project
[Display omitted] In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid agonist therapy (OAT) is facilitated in France thro...
Saved in:
Published in | The International journal of drug policy Vol. 72; pp. 61 - 68 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.10.2019
Elsevier Science Ltd Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | [Display omitted]
In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid agonist therapy (OAT) is facilitated in France through delivery in primary care, and individuals with opioid dependence can be identified as those receiving OAT. Women with opioid dependence are especially vulnerable because of associated sex-related stigma, discrimination, and marginalization, all of which negatively interfere with access to HCV prevention and care. This study, based on data collected between 2012 and 2016 in France, aimed to assess whether (i) chronically HCV-infected women with opioid dependence had lower rates of HCV treatment uptake than their male counterparts during the same period (i.e., study period), and (ii) the advent of DAA resulted in increased treatment uptake rates in these women.
Individuals with opioid dependence were identified as those receiving OAT at least once during the study period. Analyses were based on exhaustive anonymous care delivery data from the French national healthcare reimbursement database. We used multinomial logistic regression to estimate sex-based disparities in HCV treatment uptake (DAA or pegylated-interferon (Peg-IFN)-based treatment versus no treatment) while accounting for potential confounders.
The study sample comprised 27,127 individuals, including 5640 (20.8%) women. Median [interquartile range] age was 45 [40–49] years. Between 2012 and 2016, 70.9 (women: 77.2; men: 69.3), 17.3 (14.2; 18.2) and 11.7% (8.6%; 12.5%) of the study sample received, respectively, no HCV treatment, DAA and Peg-IFN-based treatment only. After multiple adjustment for potential confounders, women were 41% (adjusted odds-ratio (AOR) [95% confidence interval (CI]): 0.59[0.53−0.65]) and 28% (0.72[0.66−0.78]) less likely than men to have had Peg-IFN-based and DAA treatment, respectively.
Despite increased HCV treatment uptake in women with opioid dependence in the DAA era, rates remain lower than for men. In the coming years, access to DAA treatment will continue to increase in France thanks to a forthcoming simplified model of HCV care which includes primary care as an entry point. Nevertheless, a greater understanding of sex-specific barriers to HCV care and the implementation of appropriate sex-specific measures remain a priority. |
---|---|
AbstractList | BACKGROUNDIn the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid agonist therapy (OAT) is facilitated in France through delivery in primary care, and individuals with opioid dependence can be identified as those receiving OAT. Women with opioid dependence are especially vulnerable because of associated sex-related stigma, discrimination, and marginalization, all of which negatively interfere with access to HCV prevention and care. This study, based on data collected between 2012 and 2016 in France, aimed to assess whether (i) chronically HCV-infected women with opioid dependence had lower rates of HCV treatment uptake than their male counterparts during the same period (i.e., study period), and (ii) the advent of DAA resulted in increased treatment uptake rates in these women. METHODSIndividuals with opioid dependence were identified as those receiving OAT at least once during the study period. Analyses were based on exhaustive anonymous care delivery data from the French national healthcare reimbursement database. We used multinomial logistic regression to estimate sex-based disparities in HCV treatment uptake (DAA or pegylated-interferon (Peg-IFN)-based treatment versus no treatment) while accounting for potential confounders. RESULTSThe study sample comprised 27,127 individuals, including 5640 (20.8%) women. Median [interquartile range] age was 45 [40-49] years. Between 2012 and 2016, 70.9 (women: 77.2; men: 69.3), 17.3 (14.2; 18.2) and 11.7% (8.6%; 12.5%) of the study sample received, respectively, no HCV treatment, DAA and Peg-IFN-based treatment only. After multiple adjustment for potential confounders, women were 41% (adjusted odds-ratio (AOR) [95% confidence interval (CI]): 0.59[0.53-0.65]) and 28% (0.72[0.66-0.78]) less likely than men to have had Peg-IFN-based and DAA treatment, respectively. CONCLUSIONDespite increased HCV treatment uptake in women with opioid dependence in the DAA era, rates remain lower than for men. In the coming years, access to DAA treatment will continue to increase in France thanks to a forthcoming simplified model of HCV care which includes primary care as an entry point. Nevertheless, a greater understanding of sex-specific barriers to HCV care and the implementation of appropriate sex-specific measures remain a priority. BACKGROUND:In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid agonist therapy (OAT) is facilitated in France through delivery in primary care, and individuals with opioid dependence can be identified as those receiving OAT. Women with opioid dependence are especially vulnerable because of associated sex-related stigma, discrimination, and marginalization, all of which negatively interfere with access to HCV prevention and care. This study, based on data collected between 2012 and 2016 in France, aimed to assess whether (i) chronically HCV-infected women with opioid dependence had lower rates of HCV treatment uptake than their male counterparts during the same period (i.e., study period), and (ii) the advent of DAA resulted in increased treatment uptake rates in these women.METHODS:Individuals with opioid dependence were identified as those receiving OAT at least once during the study period. Analyses were based on exhaustive anonymous care delivery data from the French national healthcare reimbursement database. We used multinomial logistic regression to estimate sex-based disparities in HCV treatment uptake (DAA or pegylated-interferon (Peg-IFN)-based treatment versus no treatment) while accounting for potential confounders.RESULTS:The study sample comprised 27,127 individuals, including 5640 (20.8%) women. Median [interquartile range] age was 45 [40-49] years. Between 2012 and 2016, 70.9 (women: 77.2; men: 69.3), 17.3 (14.2; 18.2) and 11.7% (8.6%; 12.5%) of the study sample received, respectively, no HCV treatment, DAA and Peg-IFN-based treatment only. After multiple adjustment for potential confounders, women were 41% (adjusted odds-ratio (AOR) [95% confidence interval (CI]): 0.59[0.53-0.65]) and 28% (0.72[0.66-0.78]) less likely than men to have had Peg-IFN-based and DAA treatment, respectively.CONCLUSION:Despite increased HCV treatment uptake in women with opioid dependence in the DAA era, rates remain lower than for men. In the coming years, access to DAA treatment will continue to increase in France thanks to a forthcoming simplified model of HCV care which includes primary care as an entry point. Nevertheless, a greater understanding of sex-specific barriers to HCV care and the implementation of appropriate sex-specific measures remain a priority. In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid agonist therapy (OAT) is facilitated in France through delivery in primary care, and individuals with opioid dependence can be identified as those receiving OAT. Women with opioid dependence are especially vulnerable because of associated sex-related stigma, discrimination, and marginalization, all of which negatively interfere with access to HCV prevention and care. This study, based on data collected between 2012 and 2016 in France, aimed to assess whether (i) chronically HCV-infected women with opioid dependence had lower rates of HCV treatment uptake than their male counterparts during the same period (i.e., study period), and (ii) the advent of DAA resulted in increased treatment uptake rates in these women. Individuals with opioid dependence were identified as those receiving OAT at least once during the study period. Analyses were based on exhaustive anonymous care delivery data from the French national healthcare reimbursement database. We used multinomial logistic regression to estimate sex-based disparities in HCV treatment uptake (DAA or pegylated-interferon (Peg-IFN)-based treatment versus no treatment) while accounting for potential confounders. The study sample comprised 27,127 individuals, including 5640 (20.8%) women. Median [interquartile range] age was 45 [40-49] years. Between 2012 and 2016, 70.9 (women: 77.2; men: 69.3), 17.3 (14.2; 18.2) and 11.7% (8.6%; 12.5%) of the study sample received, respectively, no HCV treatment, DAA and Peg-IFN-based treatment only. After multiple adjustment for potential confounders, women were 41% (adjusted odds-ratio (AOR) [95% confidence interval (CI]): 0.59[0.53-0.65]) and 28% (0.72[0.66-0.78]) less likely than men to have had Peg-IFN-based and DAA treatment, respectively. Despite increased HCV treatment uptake in women with opioid dependence in the DAA era, rates remain lower than for men. In the coming years, access to DAA treatment will continue to increase in France thanks to a forthcoming simplified model of HCV care which includes primary care as an entry point. Nevertheless, a greater understanding of sex-specific barriers to HCV care and the implementation of appropriate sex-specific measures remain a priority. [Display omitted] In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid agonist therapy (OAT) is facilitated in France through delivery in primary care, and individuals with opioid dependence can be identified as those receiving OAT. Women with opioid dependence are especially vulnerable because of associated sex-related stigma, discrimination, and marginalization, all of which negatively interfere with access to HCV prevention and care. This study, based on data collected between 2012 and 2016 in France, aimed to assess whether (i) chronically HCV-infected women with opioid dependence had lower rates of HCV treatment uptake than their male counterparts during the same period (i.e., study period), and (ii) the advent of DAA resulted in increased treatment uptake rates in these women. Individuals with opioid dependence were identified as those receiving OAT at least once during the study period. Analyses were based on exhaustive anonymous care delivery data from the French national healthcare reimbursement database. We used multinomial logistic regression to estimate sex-based disparities in HCV treatment uptake (DAA or pegylated-interferon (Peg-IFN)-based treatment versus no treatment) while accounting for potential confounders. The study sample comprised 27,127 individuals, including 5640 (20.8%) women. Median [interquartile range] age was 45 [40–49] years. Between 2012 and 2016, 70.9 (women: 77.2; men: 69.3), 17.3 (14.2; 18.2) and 11.7% (8.6%; 12.5%) of the study sample received, respectively, no HCV treatment, DAA and Peg-IFN-based treatment only. After multiple adjustment for potential confounders, women were 41% (adjusted odds-ratio (AOR) [95% confidence interval (CI]): 0.59[0.53−0.65]) and 28% (0.72[0.66−0.78]) less likely than men to have had Peg-IFN-based and DAA treatment, respectively. Despite increased HCV treatment uptake in women with opioid dependence in the DAA era, rates remain lower than for men. In the coming years, access to DAA treatment will continue to increase in France thanks to a forthcoming simplified model of HCV care which includes primary care as an entry point. Nevertheless, a greater understanding of sex-specific barriers to HCV care and the implementation of appropriate sex-specific measures remain a priority. Background: In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid agonist therapy (OAT) is facilitated in France through delivery in primary care, and individuals with opioid dependence can be identified as those receiving OAT. Women with opioid dependence are especially vulnerable because of associated sex-related stigma, discrimination, and marginalization, all of which negatively interfere with access to HCV prevention and care. This study, based on data collected between 2012 and 2016 in France, aimed to assess whether (i) chronically HCV-infected women with opioid dependence had lower rates of HCV treatment uptake than their male counterparts during the same period (i.e., study period), and (ii) the advent of DAA resulted in increased treatment uptake rates in these women. Methods: Individuals with opioid dependence were identified as those receiving OAT at least once during the study period. Analyses were based on exhaustive anonymous care delivery data from the French national healthcare reimbursement database. We used multinomial logistic regression to estimate sex-based disparities in HCV treatment uptake (DAA or pegylated-interferon (Peg-IFN)-based treatment versus no treatment) while accounting for potential confounders. Results: The study sample comprised 27,127 individuals, including 5640 (20.8%) women. Median [interquartile range] age was 45 [40–49] years. Between 2012 and 2016, 70.9 (women: 77.2; men: 69.3), 17.3 (14.2; 18.2) and 11.7% (8.6%; 12.5%) of the study sample received, respectively, no HCV treatment, DAA and Peg-IFN-based treatment only. After multiple adjustment for potential confounders, women were 41% (adjusted odds-ratio (AOR) [95% confidence interval (CI]): 0.59[0.53−0.65]) and 28% (0.72[0.66−0.78]) less likely than men to have had Peg-IFN-based and DAA treatment, respectively. Conclusion: Despite increased HCV treatment uptake in women with opioid dependence in the DAA era, rates remain lower than for men. In the coming years, access to DAA treatment will continue to increase in France thanks to a forthcoming simplified model of HCV care which includes primary care as an entry point. Nevertheless, a greater understanding of sex-specific barriers to HCV care and the implementation of appropriate sex-specific measures remain a priority. |
Author | Mathurin, Philippe Carrieri, Maria Patrizia Di Beo, Vincent Bailly, François Rojas Rojas, Teresa Coste, Marion Marcellin, Fabienne Barre, Tangui Protopopescu, Camelia Authier, Nicolas Delorme, Jessica Rolland, Benjamin |
Author_xml | – sequence: 1 givenname: Teresa orcidid: 0000-0003-1536-3675 surname: Rojas Rojas fullname: Rojas Rojas, Teresa organization: Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France – sequence: 2 givenname: Vincent surname: Di Beo fullname: Di Beo, Vincent organization: Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France – sequence: 3 givenname: Jessica surname: Delorme fullname: Delorme, Jessica organization: Université Clermont Auvergne, CHU Clermont-Ferrand, Inserm 1107, Neuro-Dol, Service de Pharmacologie médicale, Centres Addictovigilance et Pharmacovigilance, Clermont-Ferrand, France – sequence: 4 givenname: Tangui surname: Barre fullname: Barre, Tangui organization: Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France – sequence: 5 givenname: Philippe surname: Mathurin fullname: Mathurin, Philippe organization: Université Lille, Inserm, CHU Lille, U995 – LIRIC – Lille Inflammation Research International Center, Lille, France – sequence: 6 givenname: Camelia surname: Protopopescu fullname: Protopopescu, Camelia organization: Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France – sequence: 7 givenname: François surname: Bailly fullname: Bailly, François organization: Service d'hépatologie et d’addictologie, Groupe Hospitalier Nord, Lyon, France – sequence: 8 givenname: Marion orcidid: 0000-0001-9005-240X surname: Coste fullname: Coste, Marion organization: Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France – sequence: 9 givenname: Nicolas surname: Authier fullname: Authier, Nicolas organization: Université Clermont Auvergne, CHU Clermont-Ferrand, Inserm 1107, Neuro-Dol, Service de Pharmacologie médicale, Centres Addictovigilance et Pharmacovigilance, Clermont-Ferrand, France – sequence: 10 givenname: Maria Patrizia orcidid: 0000-0002-6794-4837 surname: Carrieri fullname: Carrieri, Maria Patrizia email: maria-patrizia.carrieri@inserm.fr, pmcarrieri@aol.com organization: Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France – sequence: 11 givenname: Benjamin surname: Rolland fullname: Rolland, Benjamin organization: Service Universitaire d’Addictologie de Lyon (SUAL), CH Le Vinatier, Université de Lyon, UCBL, 69500, Bron, France – sequence: 12 givenname: Fabienne surname: Marcellin fullname: Marcellin, Fabienne organization: Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31129024$$D View this record in MEDLINE/PubMed https://inserm.hal.science/inserm-02272320$$DView record in HAL |
BookMark | eNp9kc1uEzEQgC1URNPCGyBkiQsHEsb2ejfLAWkVKKkUtRINXC3HniQOib3Yu4n6ALw3jtL2wKEny55vfjzfBTnzwSMhbxmMGLDy02ZkY79qw4gDq0cgR8DECzJg40oMi0qOz8gAaimHopb1OblIaQMABSvYK3IuGOM18GJA_s7CASOdTn7RLqLudug72red_o3UeXoI-YEe1oGu9R5pRINuj5aG1gVnqV4F71JHuzVG3d7TBS5DRKq9pbaPzq-OEfq1aWiOf6bzfGluftzRq-Zm3txd39I2hg2a7jV5udTbhG8ezkvy8-rbfDIdzm6_X0-a2dAUleiGshSlYWNeVGXBUNRghLTVkldGL0oouREW6tKW9UJzLYsqrwEWYmxLhtqUNReX5OOp7lpvVRvdTsd7FbRT02amnE8Ydwo4r7jgsGcZ_3DC85h_ekyd2rlkcLvVHkOfFM9cdiFkndH3_6Gb0EefP6O4AAkgZVVkqjhRJoaUIi6fhmCgjlbVRp2sqqNVBVLl8jnt3UPxfrFD-5T0qDEDX04A5uXtHUaVjENv0LqsrFM2uOc7_AN9zrPQ |
CitedBy_id | crossref_primary_10_1093_cid_ciaa571 crossref_primary_10_1007_s11136_023_03496_w crossref_primary_10_1111_dar_13414 crossref_primary_10_1080_00952990_2021_1983821 crossref_primary_10_1186_s12954_022_00640_6 crossref_primary_10_1016_j_drugpo_2024_104477 crossref_primary_10_1016_j_drugpo_2023_104311 crossref_primary_10_1111_jvh_13378 crossref_primary_10_4254_wjh_v14_i1_1 crossref_primary_10_3138_canlivj_2019_0028 crossref_primary_10_1016_j_drugpo_2024_104394 crossref_primary_10_1111_liv_14634 crossref_primary_10_1111_dar_13688 crossref_primary_10_1016_S0140_6736_21_01701_3 crossref_primary_10_1111_dar_13723 crossref_primary_10_1016_j_clinre_2022_101918 crossref_primary_10_1111_dar_13802 crossref_primary_10_1016_j_drugalcdep_2021_108525 crossref_primary_10_1016_j_drugpo_2022_103654 crossref_primary_10_1016_j_drugpo_2023_103954 crossref_primary_10_1016_j_drugpo_2021_103359 crossref_primary_10_1016_j_drugpo_2023_104044 crossref_primary_10_1093_ofid_ofz426 crossref_primary_10_1016_j_drugpo_2019_07_016 crossref_primary_10_1186_s12954_022_00702_9 |
Cites_doi | 10.1016/j.ijid.2018.03.004 10.1371/journal.pone.0112328 10.1016/S0140-6736(11)61097-0 10.1111/j.1465-3362.2012.00468.x 10.1097/QAD.0000000000001039 10.1002/jia2.25013 10.1016/j.drugpo.2017.08.001 10.1089/apc.2006.0206 10.1371/journal.pone.0166451 10.1371/journal.pone.0157062 10.1016/j.jadohealth.2010.10.003 10.1080/14659890601010373 10.1111/jvh.12628 10.1111/add.14393 10.1016/j.jhep.2017.12.013 10.1186/s12879-017-2889-4 10.1089/apc.2010.0142 10.1111/jvh.12008 10.1016/j.drugalcdep.2015.09.025 10.1093/infdis/jiu057 10.1002/pds.4233 10.1016/j.jhep.2016.10.006 10.1093/cid/ciw249 10.1186/1471-2334-14-S6-S16 10.1016/j.jhep.2004.11.018 10.1371/journal.pone.0109282 10.5604/01.3001.0010.2757 10.1136/bmjopen-2014-004988 10.1016/j.respe.2017.05.004 10.1111/liv.14043 10.1097/QAI.0000000000001816 10.1111/ajad.12784 10.3109/14659891.2016.1144805 10.1093/jurban/jtg137 10.1111/jvh.13013 10.1186/s12954-015-0067-9 10.1186/s41124-018-0033-8 10.1097/QAI.0000000000000659 10.1111/jvh.12475 10.1016/S2214-109X(17)30375-3 10.1093/cid/cix768 10.1016/j.drugalcdep.2007.09.008 10.1111/jvh.12129 10.1080/07370016.2018.1404832 10.3109/00952990.2011.596982 10.1016/S2468-1253(17)30284-4 10.1016/j.drugalcdep.2011.12.020 10.1097/COH.0b013e3283536ab2 |
ContentType | Journal Article |
Copyright | 2019 Elsevier B.V. Copyright © 2019 Elsevier B.V. All rights reserved. Copyright Elsevier Science Ltd. Oct 2019 Distributed under a Creative Commons Attribution 4.0 International License |
Copyright_xml | – notice: 2019 Elsevier B.V. – notice: Copyright © 2019 Elsevier B.V. All rights reserved. – notice: Copyright Elsevier Science Ltd. Oct 2019 – notice: Distributed under a Creative Commons Attribution 4.0 International License |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QJ 7TQ 8BJ DHY DON FQK JBE 7X8 1XC VOOES |
DOI | 10.1016/j.drugpo.2019.05.013 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Applied Social Sciences Index & Abstracts (ASSIA) PAIS Index International Bibliography of the Social Sciences (IBSS) PAIS International PAIS International (Ovid) International Bibliography of the Social Sciences International Bibliography of the Social Sciences MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef International Bibliography of the Social Sciences (IBSS) Applied Social Sciences Index and Abstracts (ASSIA) PAIS International MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE International Bibliography of the Social Sciences (IBSS) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Social Welfare & Social Work Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-4758 |
EndPage | 68 |
ExternalDocumentID | oai_HAL_inserm_02272320v1 10_1016_j_drugpo_2019_05_013 31129024 S0955395919301355 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | France |
GeographicLocations_xml | – name: France |
GroupedDBID | --- --K --M ..I .1- .FO .~1 0R~ 0SF 1B1 1P~ 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AACTN AAEDT AAEDW AAFJI AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAWTL AAXUO ABBQC ABFNM ABIVO ABJNI ABLVK ABMAC ABMMH ABMZM ABXDB ABYKQ ABZDS ACDAQ ACGFS ACHQT ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK AKYCK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AOMHK ASPBG AVARZ AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM LCYCR M41 MO0 N9A NCXOZ O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. PQQKQ PRBVW Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSB SSH SSO SSP SSZ T5K UHS Z5R ~G- ADVLN AKRWK CGR CUY CVF ECM EIF NPM AAXKI AAYXX CITATION 7QJ 7TQ 8BJ DHY DON FQK JBE 7X8 1XC VOOES |
ID | FETCH-LOGICAL-c473t-5636c18247641e390c35d7f27cab6062c3d096d69ba2a5474750b38d61eac6923 |
IEDL.DBID | .~1 |
ISSN | 0955-3959 |
IngestDate | Wed Sep 04 07:23:23 EDT 2024 Fri Aug 16 04:20:08 EDT 2024 Mon Sep 23 13:45:37 EDT 2024 Thu Sep 12 16:36:18 EDT 2024 Tue Aug 27 13:48:53 EDT 2024 Fri Feb 23 02:33:08 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Women Direct acting antivirals Opioid agonist therapy Hepatitis C virus Pegylated interferon Barrier to care |
Language | English |
License | Copyright © 2019 Elsevier B.V. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c473t-5636c18247641e390c35d7f27cab6062c3d096d69ba2a5474750b38d61eac6923 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-6794-4837 0000-0001-9005-240X 0000-0003-1536-3675 0000-0002-6252-8316 0000-0001-8853-3829 0000-0003-3447-2025 0000-0002-1236-0383 0000-0002-3439-8868 0000-0002-8666-3635 |
OpenAccessLink | https://inserm.hal.science/inserm-02272320 |
PMID | 31129024 |
PQID | 2305005574 |
PQPubID | 186238 |
PageCount | 8 |
ParticipantIDs | hal_primary_oai_HAL_inserm_02272320v1 proquest_miscellaneous_2232101359 proquest_journals_2305005574 crossref_primary_10_1016_j_drugpo_2019_05_013 pubmed_primary_31129024 elsevier_sciencedirect_doi_10_1016_j_drugpo_2019_05_013 |
PublicationCentury | 2000 |
PublicationDate | 2019-10-01 |
PublicationDateYYYYMMDD | 2019-10-01 |
PublicationDate_xml | – month: 10 year: 2019 text: 2019-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands – name: Amsterdam |
PublicationTitle | The International journal of drug policy |
PublicationTitleAlternate | Int J Drug Policy |
PublicationYear | 2019 |
Publisher | Elsevier B.V Elsevier Science Ltd Elsevier |
Publisher_xml | – name: Elsevier B.V – name: Elsevier Science Ltd – name: Elsevier |
References | Back, Payne, Wahlquist, Carter, Stroud, Haynes (bib0025) 2011; 37 Carré, Perronnin (bib0065) 2018 Deuffic-Burban, Boursier, Leroy, Yazdanpanah, Castera, Mathurin (bib0095) 2017; 66 HAS (bib0145) 2016 Kwon, Dore, Grebely, Hajarizadeh, Guy, Cunningham (bib0180) 2019; 26 Delile, de Ledinghen, Jauffret-Roustide, Roux, Reiller, Foucher (bib0080) 2018; 3 Esmaeili, Mirzazadeh, Carter, Esmaeili, Hajarizadeh, Sacks (bib0105) 2017; 24 Marshall, Cunningham, Nielsen, Aghemo, Alho, Backmund (bib0210) 2018; 3 Liakina, Hamid, Tanaka, Olafsson, Sharara, Alavian (bib0200) 2015; 22 Esmaeili, Mirzazadeh, Morris, Hajarizadeh, Sacks, Maher (bib0110) 2018; 66 Morris, Bates, Andrew, Hahn, Page, Maher (bib0235) 2015; 156 Miller, Fielden, Tyndall, Zhang, Gibson, Shannon (bib0220) 2011; 49 Smyth, Francheville, Rankin, Beck, Hoare, Materniak (bib0285) 2017; 16 Des Jarlais, Feelemyer, Modi, Arasteh, Hagan (bib0085) 2012; 124 The European Monitoring Centre fro Drugs and Drug Addiction (bib0305) 2009 Kanwal, Kramer, El-Serag, Frayne, Clark, Cao (bib0170) 2016; 63 Bezin, Duong, Lassalle, Droz, Pariente, Blin (bib0040) 2017; 26 Scott, Ólafsson, Gottfreðsson, Tyrfingsson, Rúnarsdóttir, Hansdottir (bib0280) 2018; 68 Inserm (bib0155) 2010 Assurance Maladie (bib0020) 2007 Socías, Ti, Wood, Nosova, Hull, Hayashi (bib0290) 2019 Campbell, Barbosa-Leiker, Hatch-Maillette, Mennenga, Pavlicova, Scodes (bib0060) 2018; 27 Beck, Obradovic, Palle, Brisacier, Cadet-Taïrou, Diaz-Gomez (bib0035) 2017; 117 Iversen, Grebely, Topp, Wand, Dore, Maher (bib0160) 2014; 21 Prescrire (bib0265) 2018; 38 Swan, Long, Carr, Flanagan, Irish, Keating (bib0295) 2010; 24 Tracy, Hahn, Fuller Lewis, Evans, Briceño, Morris (bib0310) 2014; 4 Baden, Rockstroh, Buti (bib0030) 2014; 209 European Monitoring Centre for Drugs and Drug Addiction (bib0115) 2018 WHO (bib0330) 2018 WHO (bib0325) 2016 Nelson, Mathers, Cowie, Hagan, Des Jarlais, Horyniak (bib0255) 2011; 378 Saeed, Strumpf, Moodie, Young, Nitulescu, Cox (bib0275) 2017; 20 Roux, Rojas Castro, Ndiaye, Debrus, Protopopescu, Le Gall (bib0270) 2016; 11 Broers, Helbling, François, Schmid, Chuard, Hadengue (bib0045) 2005; 42 Degenhardt, Peacock, Colledge, Leung, Grebely, Vickerman (bib0075) 2017; 5 Des Jarlais, Kerr, Carrieri, Feelemyer, Arasteh (bib0090) 2016; 30 HAS (bib0150) 2017 Khuat, Morrow, Nguyen, Armstrong (bib0175) 2015; 12 Tuppin, Rudant, Constantinou, Gastaldi-Ménager, Rachas, de Roquefeuil (bib0320) 2017; 65 Grebely, Bruneau, Bruggmann, Harris, Hickman, Rhodes (bib0130) 2017; 47 Bruggmann (bib0055) 2012; 19 Ministère des solidarités et de la Santé (bib0225) 2018 Assefa, Hill, Williams (bib0015) 2018; 70 Iversen, Page, Madden, Maher (bib0165) 2015; 69 Acheampong, Striley, Cottler (bib0005) 2017; 22 Brouard, Boussac-Zarebska, Silvain, Durand, de Lédinghen, Pillonel (bib0050) 2017; 17 Carrieri, Michel, Lions, Cohen, Vray, Mora (bib0070) 2014; 9 OFDT (bib0260) 2015 Treloar, Hull, Dore, Grebely (bib0315) 2012; 31 El-Bassel, Wechsberg, Shaw (bib0100) 2012; 7 NDARC (bib0250) 2010 Ministère des Solidarités et de la Santé (bib0230) 2017 AFEF (bib0010) 2018 Temple-Smith, Stoové, Smith, O’Brien, Mitchell, Banwell (bib0300) 2007; 12 Grebely, Larney, Peacock, Colledge, Leung, Hickman (bib0140) 2019; 114 Morris, Evans, Montgomery, Yu, Briceno, Page (bib0240) 2014; 9 Lally, Montstream-Quas, Tanaka, Tedeschi, Morrow (bib0185) 2008; 22 Lazarus, Sperle, Maticic, Wiessing (bib0195) 2014; 14 Evans, Hahn, Page-Shafer, Lum, Stein, Davidson (bib0120) 2003; 80 Lazar, Davenport (bib0190) 2018; 35 Mackesy-Amiti, Boodram, Handanagic, Paz-Bailey, Prachand, Broz (bib0205) 2018; 79 Geeraert, Rivollier (bib0125) 2014; 790 Mutatayi (bib0245) 2014 Midgard, Bramness, Skurtveit, Haukeland, Dalgard (bib0215) 2016; 11 Grebely, Genoway, Raffa, Dhadwal, Rajan, Showler (bib0135) 2008; 93 Deuffic-Burban (10.1016/j.drugpo.2019.05.013_bib0095) 2017; 66 Grebely (10.1016/j.drugpo.2019.05.013_bib0130) 2017; 47 Des Jarlais (10.1016/j.drugpo.2019.05.013_bib0090) 2016; 30 Liakina (10.1016/j.drugpo.2019.05.013_bib0200) 2015; 22 Khuat (10.1016/j.drugpo.2019.05.013_bib0175) 2015; 12 WHO (10.1016/j.drugpo.2019.05.013_bib0330) 2018 Acheampong (10.1016/j.drugpo.2019.05.013_bib0005) 2017; 22 HAS (10.1016/j.drugpo.2019.05.013_bib0145) 2016 Tuppin (10.1016/j.drugpo.2019.05.013_bib0320) 2017; 65 Carrieri (10.1016/j.drugpo.2019.05.013_bib0070) 2014; 9 Saeed (10.1016/j.drugpo.2019.05.013_bib0275) 2017; 20 Kwon (10.1016/j.drugpo.2019.05.013_bib0180) 2019; 26 Bruggmann (10.1016/j.drugpo.2019.05.013_bib0055) 2012; 19 Grebely (10.1016/j.drugpo.2019.05.013_bib0140) 2019; 114 Geeraert (10.1016/j.drugpo.2019.05.013_bib0125) 2014; 790 Ministère des Solidarités et de la Santé (10.1016/j.drugpo.2019.05.013_bib0230) 2017 Scott (10.1016/j.drugpo.2019.05.013_bib0280) 2018; 68 Ministère des solidarités et de la Santé (10.1016/j.drugpo.2019.05.013_bib0225) 2018 Delile (10.1016/j.drugpo.2019.05.013_bib0080) 2018; 3 Smyth (10.1016/j.drugpo.2019.05.013_bib0285) 2017; 16 Bezin (10.1016/j.drugpo.2019.05.013_bib0040) 2017; 26 Morris (10.1016/j.drugpo.2019.05.013_bib0240) 2014; 9 Esmaeili (10.1016/j.drugpo.2019.05.013_bib0105) 2017; 24 Roux (10.1016/j.drugpo.2019.05.013_bib0270) 2016; 11 Back (10.1016/j.drugpo.2019.05.013_bib0025) 2011; 37 Iversen (10.1016/j.drugpo.2019.05.013_bib0165) 2015; 69 NDARC (10.1016/j.drugpo.2019.05.013_bib0250) 2010 OFDT (10.1016/j.drugpo.2019.05.013_bib0260) 2015 Evans (10.1016/j.drugpo.2019.05.013_bib0120) 2003; 80 HAS (10.1016/j.drugpo.2019.05.013_bib0150) 2017 Assefa (10.1016/j.drugpo.2019.05.013_bib0015) 2018; 70 Esmaeili (10.1016/j.drugpo.2019.05.013_bib0110) 2018; 66 WHO (10.1016/j.drugpo.2019.05.013_bib0325) 2016 Marshall (10.1016/j.drugpo.2019.05.013_bib0210) 2018; 3 Baden (10.1016/j.drugpo.2019.05.013_bib0030) 2014; 209 Inserm (10.1016/j.drugpo.2019.05.013_bib0155) 2010 Temple-Smith (10.1016/j.drugpo.2019.05.013_bib0300) 2007; 12 Brouard (10.1016/j.drugpo.2019.05.013_bib0050) 2017; 17 Mackesy-Amiti (10.1016/j.drugpo.2019.05.013_bib0205) 2018; 79 Prescrire (10.1016/j.drugpo.2019.05.013_bib0265) 2018; 38 Kanwal (10.1016/j.drugpo.2019.05.013_bib0170) 2016; 63 Iversen (10.1016/j.drugpo.2019.05.013_bib0160) 2014; 21 Lazarus (10.1016/j.drugpo.2019.05.013_bib0195) 2014; 14 Socías (10.1016/j.drugpo.2019.05.013_bib0290) 2019 Tracy (10.1016/j.drugpo.2019.05.013_bib0310) 2014; 4 Broers (10.1016/j.drugpo.2019.05.013_bib0045) 2005; 42 Degenhardt (10.1016/j.drugpo.2019.05.013_bib0075) 2017; 5 Mutatayi (10.1016/j.drugpo.2019.05.013_bib0245) 2014 Swan (10.1016/j.drugpo.2019.05.013_bib0295) 2010; 24 Morris (10.1016/j.drugpo.2019.05.013_bib0235) 2015; 156 AFEF (10.1016/j.drugpo.2019.05.013_bib0010) 2018 Des Jarlais (10.1016/j.drugpo.2019.05.013_bib0085) 2012; 124 Lazar (10.1016/j.drugpo.2019.05.013_bib0190) 2018; 35 Treloar (10.1016/j.drugpo.2019.05.013_bib0315) 2012; 31 Nelson (10.1016/j.drugpo.2019.05.013_bib0255) 2011; 378 Assurance Maladie (10.1016/j.drugpo.2019.05.013_bib0020) 2007 The European Monitoring Centre fro Drugs and Drug Addiction (10.1016/j.drugpo.2019.05.013_bib0305) 2009 Grebely (10.1016/j.drugpo.2019.05.013_bib0135) 2008; 93 Beck (10.1016/j.drugpo.2019.05.013_bib0035) 2017; 117 Carré (10.1016/j.drugpo.2019.05.013_bib0065) 2018 Campbell (10.1016/j.drugpo.2019.05.013_bib0060) 2018; 27 Miller (10.1016/j.drugpo.2019.05.013_bib0220) 2011; 49 Lally (10.1016/j.drugpo.2019.05.013_bib0185) 2008; 22 El-Bassel (10.1016/j.drugpo.2019.05.013_bib0100) 2012; 7 European Monitoring Centre for Drugs and Drug Addiction (10.1016/j.drugpo.2019.05.013_bib0115) 2018 Midgard (10.1016/j.drugpo.2019.05.013_bib0215) 2016; 11 |
References_xml | – volume: 9 year: 2014 ident: bib0070 article-title: Methadone induction in primary care for opioid dependence: A pragmatic randomized trial (ANRS Methaville) publication-title: PLoS One contributor: fullname: Mora – volume: 11 year: 2016 ident: bib0270 article-title: Increased uptake of HCV testing through a community-based educational intervention in difficult-to-reach people who inject drugs: Results from the ANRS-AERLI study publication-title: PLoS One contributor: fullname: Le Gall – volume: 790 start-page: 14 year: 2014 end-page: 18 ident: bib0125 article-title: Access to care for vulnerable populations publication-title: Soins – La revue de référence infirmière contributor: fullname: Rivollier – volume: 79 start-page: 305 year: 2018 end-page: 314 ident: bib0205 article-title: Latent classes of sexual risk behavior and engagement in outreach, intervention and prevention services among women who inject drugs across 20 US cities publication-title: Journal of Acquired Immune Deficiency Syndromes (1999) contributor: fullname: Broz – volume: 38 start-page: 420 year: 2018 end-page: 421 ident: bib0265 article-title: Antiviraux dits à action directe dans l’hépatite C: en ville aussi publication-title: Prescrire contributor: fullname: Prescrire – year: 2018 ident: bib0330 article-title: WHO International classification of diseases (ICD) contributor: fullname: WHO – volume: 70 start-page: 65 year: 2018 end-page: 68 ident: bib0015 article-title: Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment publication-title: International Journal of Infectious Diseases: IJID contributor: fullname: Williams – volume: 93 start-page: 141 year: 2008 end-page: 147 ident: bib0135 article-title: Barriers associated with the treatment of hepatitis C virus infection among illicit drug users publication-title: Drug and Alcohol Dependence contributor: fullname: Showler – volume: 37 start-page: 313 year: 2011 end-page: 323 ident: bib0025 article-title: Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial publication-title: The American Journal of Drug and Alcohol Abuse contributor: fullname: Haynes – year: 2017 ident: bib0230 article-title: Accès universel aux traitements innovants contre l’hépatite C contributor: fullname: Ministère des Solidarités et de la Santé – volume: 24 start-page: 753 year: 2010 end-page: 762 ident: bib0295 article-title: Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration publication-title: AIDS Patient Care and STDs contributor: fullname: Keating – year: 2016 ident: bib0145 article-title: Prise en charge de l’hépatite C par les médicaments antiviraux à action directe (AAD) contributor: fullname: HAS – start-page: 2010 year: 2014 end-page: 2011 ident: bib0245 article-title: OFDT. Accueil addictologique et médicosocial de femmes toxicodépendantes contributor: fullname: Mutatayi – volume: 80 start-page: 137 year: 2003 end-page: 146 ident: bib0120 article-title: Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study) publication-title: Journal of Urban Health: Bulletin of the New York Academy of Medicine contributor: fullname: Davidson – volume: 12 start-page: 35 year: 2015 ident: bib0175 article-title: Social context, diversity and risk among women who inject drugs in Vietnam: Descriptive findings from a cross-sectional survey publication-title: Harm Reduction Journal contributor: fullname: Armstrong – start-page: 8 year: 2007 ident: bib0020 article-title: LES ALD des bénéficiaires de la CMU-C. Points de repère contributor: fullname: Assurance Maladie – volume: 209 start-page: S81 year: 2014 end-page: 85 ident: bib0030 article-title: Natural history and management of hepatitis C: Does sex play a role? publication-title: The Journal of Infectious Diseases contributor: fullname: Buti – volume: 12 start-page: 59 year: 2007 end-page: 70 ident: bib0300 article-title: Gender differences in seeking care for hepatitis C in Australia publication-title: Journal of Substance Use contributor: fullname: Banwell – year: 2010 ident: bib0155 article-title: Réduction des risques chez les usagers de drogues contributor: fullname: Inserm – volume: 5 start-page: e1192 year: 2017 end-page: e1207 ident: bib0075 article-title: Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review publication-title: The Lancet Global Health contributor: fullname: Vickerman – volume: 3 year: 2018 ident: bib0080 article-title: Hepatitis C virus prevention and care for drug injectors: The French approach publication-title: Hepatology, Medicine and Policy contributor: fullname: Foucher – volume: 117 year: 2017 ident: bib0035 article-title: Usage de drogues et conséquences: quelles spécificités féminines? publication-title: Tendances contributor: fullname: Diaz-Gomez – volume: 156 start-page: 275 year: 2015 end-page: 281 ident: bib0235 article-title: More than just someone to inject drugs with: Injecting within primary injection partnerships publication-title: Drug and Alcohol Dependence contributor: fullname: Maher – year: 2019 ident: bib0290 article-title: Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting publication-title: Liver International contributor: fullname: Hayashi – volume: 3 start-page: 125 year: 2018 end-page: 133 ident: bib0210 article-title: Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe publication-title: The Lancet Gastroenterology & Hepatology contributor: fullname: Backmund – volume: 7 start-page: 326 year: 2012 end-page: 331 ident: bib0100 article-title: Dual HIV risk and vulnerabilities among women who use or inject drugs: No single prevention strategy is the answer publication-title: Current Opinion in HIV and AIDS contributor: fullname: Shaw – year: 2018 ident: bib0010 article-title: Recommandations AFEF pour l’élimination de l’infection par le virus de l’hépatite C en France contributor: fullname: AFEF – volume: 31 start-page: 918 year: 2012 end-page: 924 ident: bib0315 article-title: Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs publication-title: Drug and Alcohol Review contributor: fullname: Grebely – year: 2009 ident: bib0305 article-title: Women’s voices experiences and perceptions of women who face drug-related problems in Europe contributor: fullname: The European Monitoring Centre fro Drugs and Drug Addiction – year: 2018 ident: bib0065 article-title: Evolution de la dépense en part de complémentaire santé des bénéficiaires de la CMU-c analyse et prévision contributor: fullname: Perronnin – volume: 69 start-page: S176 year: 2015 end-page: 181 ident: bib0165 article-title: HIV, HCV, and health-related harms among women who inject drugs: Implications for prevention and treatment publication-title: Journal of Acquired Immune Deficiency Syndromes (1999) contributor: fullname: Maher – volume: 378 start-page: 571 year: 2011 end-page: 583 ident: bib0255 article-title: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews publication-title: Lancet contributor: fullname: Horyniak – year: 2018 ident: bib0225 article-title: Précarité: accès aux soins contributor: fullname: Ministère des solidarités et de la Santé – volume: 22 start-page: 4 year: 2015 end-page: 20 ident: bib0200 article-title: Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3 publication-title: Journal of Viral Hepatitis contributor: fullname: Alavian – volume: 4 year: 2014 ident: bib0310 article-title: Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: A prospective analysis from the UFO Study cohort publication-title: BMJ Open contributor: fullname: Morris – year: 2018 ident: bib0115 article-title: France country drug report 2018 contributor: fullname: European Monitoring Centre for Drugs and Drug Addiction – year: 2016 ident: bib0325 article-title: Combating hepatitis B and C to reach elimination by 2030 contributor: fullname: WHO – volume: 26 start-page: 83 year: 2019 end-page: 92 ident: bib0180 article-title: Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study publication-title: Journal of Viral Hepatitis contributor: fullname: Cunningham – volume: 30 start-page: 815 year: 2016 end-page: 826 ident: bib0090 article-title: HIV infection among persons who inject drugs: Ending old epidemics and addressing new outbreaks publication-title: AIDS (London, England) contributor: fullname: Arasteh – year: 2010 ident: bib0250 article-title: Women who inject drugs: A review of their risks, experiences and needs contributor: fullname: NDARC – volume: 16 start-page: 749 year: 2017 end-page: 758 ident: bib0285 article-title: Early successes in an open access, provincially funded hepatitis C treatment program in Prince Edward Island publication-title: Annals of Hepatology contributor: fullname: Materniak – volume: 14 start-page: S16 year: 2014 ident: bib0195 article-title: A systematic review of hepatitis C virus treatment uptake among people who inject drugs in the European Region publication-title: BMC Infectious Diseases contributor: fullname: Wiessing – volume: 22 start-page: 53 year: 2008 end-page: 64 ident: bib0185 article-title: A qualitative study among injection drug using women in Rhode island: Attitudes toward testing, treatment, and vaccination for hepatitis and HIV publication-title: AIDS Patient Care and STDs contributor: fullname: Morrow – year: 2015 ident: bib0260 article-title: Tableau de bord TSO 2015 contributor: fullname: OFDT – volume: 17 start-page: 784 year: 2017 ident: bib0050 article-title: Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015 publication-title: BMC Infectious Diseases contributor: fullname: Pillonel – volume: 35 start-page: 28 year: 2018 end-page: 37 ident: bib0190 article-title: Barriers to health care access for low income families: A review of literature publication-title: Journal of Community Health Nursing contributor: fullname: Davenport – volume: 66 start-page: 304 year: 2017 end-page: 312 ident: bib0095 article-title: Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis? publication-title: Journal of Hepatology contributor: fullname: Mathurin – volume: 66 start-page: 20 year: 2018 end-page: 28 ident: bib0110 article-title: The effect of female sex on hepatitis C incidence among people who inject drugs: Results from the international multicohort InC3 collaborative publication-title: Clinical Infectious Diseases contributor: fullname: Maher – volume: 114 start-page: 150 year: 2019 end-page: 166 ident: bib0140 article-title: Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs publication-title: Addiction (Abingdon, England) contributor: fullname: Hickman – volume: 68 start-page: 932 year: 2018 end-page: 939 ident: bib0280 article-title: Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020 publication-title: Journal of Hepatology contributor: fullname: Hansdottir – volume: 49 start-page: 36 year: 2011 end-page: 41 ident: bib0220 article-title: Individual and structural vulnerability among female youth who exchange sex for survival publication-title: The Journal of Adolescent Health contributor: fullname: Shannon – volume: 20 year: 2017 ident: bib0275 article-title: Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada publication-title: Journal of the International AIDS Society contributor: fullname: Cox – volume: 47 start-page: 26 year: 2017 end-page: 33 ident: bib0130 article-title: Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy publication-title: The International Journal of Drug Policy contributor: fullname: Rhodes – year: 2017 ident: bib0150 article-title: HAS – Commission de la Transparence – Rapport d’évaluation des antiviraux d’action directe dans le traitement de l’hépatite C. Actualisation 2017 contributor: fullname: HAS – volume: 63 start-page: 291 year: 2016 end-page: 299 ident: bib0170 article-title: Race and gender differences in the use of direct acting antiviral agents for hepatitis C virus publication-title: Clinical Infectious Diseases contributor: fullname: Cao – volume: 26 start-page: 954 year: 2017 end-page: 962 ident: bib0040 article-title: The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology publication-title: Pharmacoepidemiology and Drug Safety contributor: fullname: Blin – volume: 24 start-page: 117 year: 2017 end-page: 127 ident: bib0105 article-title: Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis publication-title: Journal of Viral Hepatitis contributor: fullname: Sacks – volume: 19 start-page: 829 year: 2012 end-page: 835 ident: bib0055 article-title: Accessing hepatitis C patients who are difficult to reach: It is time to overcome barriers publication-title: Journal of Viral Hepatitis contributor: fullname: Bruggmann – volume: 22 start-page: 90 year: 2017 end-page: 95 ident: bib0005 article-title: Prescription opioid use, illicit drug use, and sexually transmitted infections among participants from a community engagement program in North Central Florida publication-title: Journal of Substance Use contributor: fullname: Cottler – volume: 42 start-page: 323 year: 2005 end-page: 328 ident: bib0045 article-title: Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C publication-title: Journal of Hepatology contributor: fullname: Hadengue – volume: 27 start-page: 465 year: 2018 end-page: 470 ident: bib0060 article-title: Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial publication-title: The American Journal on Addictions contributor: fullname: Scodes – volume: 9 year: 2014 ident: bib0240 article-title: Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA publication-title: PLoS One contributor: fullname: Page – volume: 65 start-page: S149 year: 2017 end-page: S167 ident: bib0320 article-title: Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France publication-title: Revue D’epidemiologie Et De Sante Publique contributor: fullname: de Roquefeuil – volume: 21 start-page: 198 year: 2014 end-page: 207 ident: bib0160 article-title: Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 publication-title: Journal of Viral Hepatitis contributor: fullname: Maher – volume: 124 start-page: 95 year: 2012 end-page: 107 ident: bib0085 article-title: Are females who inject drugs at higher risk for HIV infection than males who inject drugs: An international systematic review of high seroprevalence areas publication-title: Drug and Alcohol Dependence contributor: fullname: Hagan – volume: 11 year: 2016 ident: bib0215 article-title: Hepatitis C treatment uptake among patients who have received opioid substitution treatment: A population-based study publication-title: PLoS One contributor: fullname: Dalgard – volume: 70 start-page: 65 year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0015 article-title: Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment publication-title: International Journal of Infectious Diseases: IJID doi: 10.1016/j.ijid.2018.03.004 contributor: fullname: Assefa – volume: 9 issue: 11 year: 2014 ident: 10.1016/j.drugpo.2019.05.013_bib0070 article-title: Methadone induction in primary care for opioid dependence: A pragmatic randomized trial (ANRS Methaville) publication-title: PLoS One doi: 10.1371/journal.pone.0112328 contributor: fullname: Carrieri – volume: 378 start-page: 571 issue: 9791 year: 2011 ident: 10.1016/j.drugpo.2019.05.013_bib0255 article-title: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews publication-title: Lancet doi: 10.1016/S0140-6736(11)61097-0 contributor: fullname: Nelson – volume: 31 start-page: 918 issue: 7 year: 2012 ident: 10.1016/j.drugpo.2019.05.013_bib0315 article-title: Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs publication-title: Drug and Alcohol Review doi: 10.1111/j.1465-3362.2012.00468.x contributor: fullname: Treloar – volume: 30 start-page: 815 issue: 6 year: 2016 ident: 10.1016/j.drugpo.2019.05.013_bib0090 article-title: HIV infection among persons who inject drugs: Ending old epidemics and addressing new outbreaks publication-title: AIDS (London, England) doi: 10.1097/QAD.0000000000001039 contributor: fullname: Des Jarlais – year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0010 contributor: fullname: AFEF – year: 2010 ident: 10.1016/j.drugpo.2019.05.013_bib0155 contributor: fullname: Inserm – volume: 20 issue: 3 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0275 article-title: Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada publication-title: Journal of the International AIDS Society doi: 10.1002/jia2.25013 contributor: fullname: Saeed – volume: 47 start-page: 26 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0130 article-title: Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy publication-title: The International Journal of Drug Policy doi: 10.1016/j.drugpo.2017.08.001 contributor: fullname: Grebely – year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0225 contributor: fullname: Ministère des solidarités et de la Santé – volume: 790 start-page: 14 year: 2014 ident: 10.1016/j.drugpo.2019.05.013_bib0125 article-title: Access to care for vulnerable populations publication-title: Soins – La revue de référence infirmière contributor: fullname: Geeraert – year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0150 contributor: fullname: HAS – year: 2009 ident: 10.1016/j.drugpo.2019.05.013_bib0305 contributor: fullname: The European Monitoring Centre fro Drugs and Drug Addiction – volume: 117 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0035 article-title: Usage de drogues et conséquences: quelles spécificités féminines? publication-title: Tendances contributor: fullname: Beck – volume: 22 start-page: 53 issue: 1 year: 2008 ident: 10.1016/j.drugpo.2019.05.013_bib0185 article-title: A qualitative study among injection drug using women in Rhode island: Attitudes toward testing, treatment, and vaccination for hepatitis and HIV publication-title: AIDS Patient Care and STDs doi: 10.1089/apc.2006.0206 contributor: fullname: Lally – volume: 11 issue: 11 year: 2016 ident: 10.1016/j.drugpo.2019.05.013_bib0215 article-title: Hepatitis C treatment uptake among patients who have received opioid substitution treatment: A population-based study publication-title: PLoS One doi: 10.1371/journal.pone.0166451 contributor: fullname: Midgard – year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0230 contributor: fullname: Ministère des Solidarités et de la Santé – volume: 11 issue: 6 year: 2016 ident: 10.1016/j.drugpo.2019.05.013_bib0270 article-title: Increased uptake of HCV testing through a community-based educational intervention in difficult-to-reach people who inject drugs: Results from the ANRS-AERLI study publication-title: PLoS One doi: 10.1371/journal.pone.0157062 contributor: fullname: Roux – year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0065 contributor: fullname: Carré – volume: 49 start-page: 36 issue: 1 year: 2011 ident: 10.1016/j.drugpo.2019.05.013_bib0220 article-title: Individual and structural vulnerability among female youth who exchange sex for survival publication-title: The Journal of Adolescent Health doi: 10.1016/j.jadohealth.2010.10.003 contributor: fullname: Miller – volume: 12 start-page: 59 issue: 1 year: 2007 ident: 10.1016/j.drugpo.2019.05.013_bib0300 article-title: Gender differences in seeking care for hepatitis C in Australia publication-title: Journal of Substance Use doi: 10.1080/14659890601010373 contributor: fullname: Temple-Smith – volume: 24 start-page: 117 issue: 2 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0105 article-title: Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis publication-title: Journal of Viral Hepatitis doi: 10.1111/jvh.12628 contributor: fullname: Esmaeili – volume: 114 start-page: 150 issue: 1 year: 2019 ident: 10.1016/j.drugpo.2019.05.013_bib0140 article-title: Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs publication-title: Addiction (Abingdon, England) doi: 10.1111/add.14393 contributor: fullname: Grebely – volume: 68 start-page: 932 issue: 5 year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0280 article-title: Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020 publication-title: Journal of Hepatology doi: 10.1016/j.jhep.2017.12.013 contributor: fullname: Scott – year: 2016 ident: 10.1016/j.drugpo.2019.05.013_bib0145 contributor: fullname: HAS – year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0330 contributor: fullname: WHO – volume: 17 start-page: 784 issue: 1 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0050 article-title: Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015 publication-title: BMC Infectious Diseases doi: 10.1186/s12879-017-2889-4 contributor: fullname: Brouard – volume: 24 start-page: 753 issue: 12 year: 2010 ident: 10.1016/j.drugpo.2019.05.013_bib0295 article-title: Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration publication-title: AIDS Patient Care and STDs doi: 10.1089/apc.2010.0142 contributor: fullname: Swan – volume: 19 start-page: 829 issue: 12 year: 2012 ident: 10.1016/j.drugpo.2019.05.013_bib0055 article-title: Accessing hepatitis C patients who are difficult to reach: It is time to overcome barriers publication-title: Journal of Viral Hepatitis doi: 10.1111/jvh.12008 contributor: fullname: Bruggmann – volume: 156 start-page: 275 year: 2015 ident: 10.1016/j.drugpo.2019.05.013_bib0235 article-title: More than just someone to inject drugs with: Injecting within primary injection partnerships publication-title: Drug and Alcohol Dependence doi: 10.1016/j.drugalcdep.2015.09.025 contributor: fullname: Morris – volume: 209 start-page: S81 issue: Suppl 3 year: 2014 ident: 10.1016/j.drugpo.2019.05.013_bib0030 article-title: Natural history and management of hepatitis C: Does sex play a role? publication-title: The Journal of Infectious Diseases doi: 10.1093/infdis/jiu057 contributor: fullname: Baden – volume: 26 start-page: 954 issue: 8 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0040 article-title: The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology publication-title: Pharmacoepidemiology and Drug Safety doi: 10.1002/pds.4233 contributor: fullname: Bezin – volume: 66 start-page: 304 issue: 2 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0095 article-title: Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis? publication-title: Journal of Hepatology doi: 10.1016/j.jhep.2016.10.006 contributor: fullname: Deuffic-Burban – volume: 63 start-page: 291 issue: 3 year: 2016 ident: 10.1016/j.drugpo.2019.05.013_bib0170 article-title: Race and gender differences in the use of direct acting antiviral agents for hepatitis C virus publication-title: Clinical Infectious Diseases doi: 10.1093/cid/ciw249 contributor: fullname: Kanwal – volume: 14 start-page: S16 issue: Suppl 6 year: 2014 ident: 10.1016/j.drugpo.2019.05.013_bib0195 article-title: A systematic review of hepatitis C virus treatment uptake among people who inject drugs in the European Region publication-title: BMC Infectious Diseases doi: 10.1186/1471-2334-14-S6-S16 contributor: fullname: Lazarus – volume: 42 start-page: 323 issue: 3 year: 2005 ident: 10.1016/j.drugpo.2019.05.013_bib0045 article-title: Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C publication-title: Journal of Hepatology doi: 10.1016/j.jhep.2004.11.018 contributor: fullname: Broers – volume: 9 issue: 10 year: 2014 ident: 10.1016/j.drugpo.2019.05.013_bib0240 article-title: Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA publication-title: PLoS One doi: 10.1371/journal.pone.0109282 contributor: fullname: Morris – volume: 16 start-page: 749 issue: 5 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0285 article-title: Early successes in an open access, provincially funded hepatitis C treatment program in Prince Edward Island publication-title: Annals of Hepatology doi: 10.5604/01.3001.0010.2757 contributor: fullname: Smyth – year: 2016 ident: 10.1016/j.drugpo.2019.05.013_bib0325 contributor: fullname: WHO – volume: 4 issue: 5 year: 2014 ident: 10.1016/j.drugpo.2019.05.013_bib0310 article-title: Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: A prospective analysis from the UFO Study cohort publication-title: BMJ Open doi: 10.1136/bmjopen-2014-004988 contributor: fullname: Tracy – volume: 65 start-page: S149 issue: Suppl 4 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0320 article-title: Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France publication-title: Revue D’epidemiologie Et De Sante Publique doi: 10.1016/j.respe.2017.05.004 contributor: fullname: Tuppin – year: 2019 ident: 10.1016/j.drugpo.2019.05.013_bib0290 article-title: Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting publication-title: Liver International doi: 10.1111/liv.14043 contributor: fullname: Socías – volume: 79 start-page: 305 issue: 3 year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0205 article-title: Latent classes of sexual risk behavior and engagement in outreach, intervention and prevention services among women who inject drugs across 20 US cities publication-title: Journal of Acquired Immune Deficiency Syndromes (1999) doi: 10.1097/QAI.0000000000001816 contributor: fullname: Mackesy-Amiti – volume: 38 start-page: 420 issue: 416 year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0265 article-title: Antiviraux dits à action directe dans l’hépatite C: en ville aussi publication-title: Prescrire contributor: fullname: Prescrire – volume: 27 start-page: 465 issue: 6 year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0060 article-title: Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial publication-title: The American Journal on Addictions doi: 10.1111/ajad.12784 contributor: fullname: Campbell – volume: 22 start-page: 90 issue: 1 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0005 article-title: Prescription opioid use, illicit drug use, and sexually transmitted infections among participants from a community engagement program in North Central Florida publication-title: Journal of Substance Use doi: 10.3109/14659891.2016.1144805 contributor: fullname: Acheampong – volume: 80 start-page: 137 issue: 1 year: 2003 ident: 10.1016/j.drugpo.2019.05.013_bib0120 article-title: Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study) publication-title: Journal of Urban Health: Bulletin of the New York Academy of Medicine doi: 10.1093/jurban/jtg137 contributor: fullname: Evans – volume: 26 start-page: 83 issue: 1 year: 2019 ident: 10.1016/j.drugpo.2019.05.013_bib0180 article-title: Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study publication-title: Journal of Viral Hepatitis doi: 10.1111/jvh.13013 contributor: fullname: Kwon – volume: 12 start-page: 35 year: 2015 ident: 10.1016/j.drugpo.2019.05.013_bib0175 article-title: Social context, diversity and risk among women who inject drugs in Vietnam: Descriptive findings from a cross-sectional survey publication-title: Harm Reduction Journal doi: 10.1186/s12954-015-0067-9 contributor: fullname: Khuat – start-page: 8 year: 2007 ident: 10.1016/j.drugpo.2019.05.013_bib0020 contributor: fullname: Assurance Maladie – volume: 3 year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0080 article-title: Hepatitis C virus prevention and care for drug injectors: The French approach publication-title: Hepatology, Medicine and Policy doi: 10.1186/s41124-018-0033-8 contributor: fullname: Delile – volume: 69 start-page: S176 issue: Suppl 2 year: 2015 ident: 10.1016/j.drugpo.2019.05.013_bib0165 article-title: HIV, HCV, and health-related harms among women who inject drugs: Implications for prevention and treatment publication-title: Journal of Acquired Immune Deficiency Syndromes (1999) doi: 10.1097/QAI.0000000000000659 contributor: fullname: Iversen – volume: 22 start-page: 4 issue: Suppl 4 year: 2015 ident: 10.1016/j.drugpo.2019.05.013_bib0200 article-title: Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3 publication-title: Journal of Viral Hepatitis doi: 10.1111/jvh.12475 contributor: fullname: Liakina – volume: 5 start-page: e1192 issue: 12 year: 2017 ident: 10.1016/j.drugpo.2019.05.013_bib0075 article-title: Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review publication-title: The Lancet Global Health doi: 10.1016/S2214-109X(17)30375-3 contributor: fullname: Degenhardt – volume: 66 start-page: 20 issue: 1 year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0110 article-title: The effect of female sex on hepatitis C incidence among people who inject drugs: Results from the international multicohort InC3 collaborative publication-title: Clinical Infectious Diseases doi: 10.1093/cid/cix768 contributor: fullname: Esmaeili – volume: 93 start-page: 141 issue: 1–2 year: 2008 ident: 10.1016/j.drugpo.2019.05.013_bib0135 article-title: Barriers associated with the treatment of hepatitis C virus infection among illicit drug users publication-title: Drug and Alcohol Dependence doi: 10.1016/j.drugalcdep.2007.09.008 contributor: fullname: Grebely – volume: 21 start-page: 198 issue: 3 year: 2014 ident: 10.1016/j.drugpo.2019.05.013_bib0160 article-title: Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 publication-title: Journal of Viral Hepatitis doi: 10.1111/jvh.12129 contributor: fullname: Iversen – volume: 35 start-page: 28 issue: 1 year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0190 article-title: Barriers to health care access for low income families: A review of literature publication-title: Journal of Community Health Nursing doi: 10.1080/07370016.2018.1404832 contributor: fullname: Lazar – volume: 37 start-page: 313 issue: 5 year: 2011 ident: 10.1016/j.drugpo.2019.05.013_bib0025 article-title: Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial publication-title: The American Journal of Drug and Alcohol Abuse doi: 10.3109/00952990.2011.596982 contributor: fullname: Back – volume: 3 start-page: 125 issue: 2 year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0210 article-title: Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe publication-title: The Lancet Gastroenterology & Hepatology doi: 10.1016/S2468-1253(17)30284-4 contributor: fullname: Marshall – volume: 124 start-page: 95 issue: 1–2 year: 2012 ident: 10.1016/j.drugpo.2019.05.013_bib0085 article-title: Are females who inject drugs at higher risk for HIV infection than males who inject drugs: An international systematic review of high seroprevalence areas publication-title: Drug and Alcohol Dependence doi: 10.1016/j.drugalcdep.2011.12.020 contributor: fullname: Des Jarlais – year: 2018 ident: 10.1016/j.drugpo.2019.05.013_bib0115 contributor: fullname: European Monitoring Centre for Drugs and Drug Addiction – year: 2015 ident: 10.1016/j.drugpo.2019.05.013_bib0260 contributor: fullname: OFDT – year: 2010 ident: 10.1016/j.drugpo.2019.05.013_bib0250 contributor: fullname: NDARC – volume: 7 start-page: 326 issue: 4 year: 2012 ident: 10.1016/j.drugpo.2019.05.013_bib0100 article-title: Dual HIV risk and vulnerabilities among women who use or inject drugs: No single prevention strategy is the answer publication-title: Current Opinion in HIV and AIDS doi: 10.1097/COH.0b013e3283536ab2 contributor: fullname: El-Bassel – start-page: 2010 year: 2014 ident: 10.1016/j.drugpo.2019.05.013_bib0245 contributor: fullname: Mutatayi |
SSID | ssj0004141 |
Score | 2.3946157 |
Snippet | [Display omitted]
In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains... In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in... Background: In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently... BACKGROUNDIn the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently... BACKGROUND:In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently... |
SourceID | hal proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 61 |
SubjectTerms | Adult Antiviral Agents - administration & dosage Antiviral drugs Barrier to care Databases, Factual Delivery of Health Care - organization & administration Direct acting antivirals Discrimination Drug policy Female France Health care Health Services Accessibility Healthcare Disparities - statistics & numerical data Hepatitis Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Human health and pathology Humans Hépatology and Gastroenterology Infections Interferon Interferons - administration & dosage Life Sciences Male Marginality Medical treatment Methadone Middle Aged Narcotics Opioid agonist therapy Opioid-Related Disorders - epidemiology Opioid-Related Disorders - therapy Opioids Pegylated interferon Prevention Primary care Primary Health Care - organization & administration Prisoners Santé publique et épidémiologie Sex Factors Sexism Stigma Substance abuse treatment Uptake Women |
Title | Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project |
URI | https://dx.doi.org/10.1016/j.drugpo.2019.05.013 https://www.ncbi.nlm.nih.gov/pubmed/31129024 https://www.proquest.com/docview/2305005574/abstract/ https://search.proquest.com/docview/2232101359 https://inserm.hal.science/inserm-02272320 |
Volume | 72 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLbGuHBBMH6FlekhwU4LbWI7P7hFharAqCbWwW6WHTtrGEuqrh3qhRv_N89x0orDhMQxtiNbeS_P30ve95mQVzpNdMEZ9eO8SHyWRqmvZB75ehBozhRVSW4Jzp8n0fiMfTzn5ztk2HFhbFllG_tdTG-iddvSb59mf16W_VMrnkZTniIEQRzDLdGc4WaEPv3m17bMg7nTK-1g347u6HNNjZderC7mlgIYpE6_k962Pd2Z2TrJ20BosxmNHpD7LYqEzC30Idkx1R45PHEy1OsjmG5ZVddHcAgnW4Hq9R7pOU4ufDM_Crkw2N811IvLR-T3sT05DcbDr7ApQ4fVfCkvDZQVNJoN8HNWw0zeGMCnZzBiaqjnZV1qkBe1FeMFR-xagzIIiw3ISoOjRNoeeJdlgP1v7Uohm3w5hVE2mWYY2aH9NvSYnI3eT4djvz2twc9ZTJc-j2iUY7bC4ogFhqaDnHIdF2GcS4VZUphTjemSjlIlQ8kZpjF8oGiiowBjf4Q48wnZrerKPCOg0kKqRDGDuRoraJgEcSENLWSholCZ2CN-ZyQxd6IcoqtW-y6cUYU1qhhwgUb1SNxZUvzlXAL3jX_c-RoNv5nEanGPs2NRVhgfroSVX0REOrgJPNLrXEO0QeBaYHbHG40z5pGXm258fe0_GVmZeoVjQkuiQvdNPfLUudRmNmqxMGKo5_-9_H1yz1654sMe2V0uVuYFgqilOmjekgNyN_vwaTz5A3O1Gjc |
link.rule.ids | 230,315,786,790,891,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELa27gFeEIxfhQKHBHtatCa284O3qFBlrKsm1sHeLDt21jBIqq4d6h_A_825TlrxMCHx6nMUK3c5f5fc95mQdzqJdcEZ9aK8iD2WhImnZB56uu9rzhRVcW4JzqfjMLtgny_55Q4ZtFwY21bZ5H6X09fZuhk5ap7m0awsj86teBpNeIIQBHEM57tkj_HIZx2ylx6fZOMtPdIdYGnne_aClkG3bvPS8-XVzLIA_cRJeNK7dqjdqW2VvAuHrvej4UPyoAGSkLq1PiI7ptonB2dOiXp1CJMtsermEA7gbKtRvdonPUfLhW_mRyHnBu3tQD2_fkx-j-zhaZANvsKmEx2Ws4W8NlBWsJZtgF_TGqby1gA-QINJU0M9K-tSg7yqrR4vOG7XCpRBZGxAVhocK9Ja4GOaAto_2JVCOv5yDsN0PEkxuUPzeegJuRh-mgwyrzmwwctZRBceD2mYY8HCopD5hib9nHIdFUGUS4WFUpBTjRWTDhMlA8kZVjK8r2isQx_Tf4hQ8ynpVHVlnhNQSSFVrJjBco0VNIj9qJCGFrJQYaBM1CVe6yQxc7ocom1Y-y6cU4V1quhzgU7tkqj1pPgrvgRuHf-48j06fnMTK8edpSNRVpgifgqrwIigtH_rd0mvDQ3R5IEbgQUeX8ucsS55uzHjG2x_y8jK1EucE1geFUZw0iXPXEht7kYtHEYY9eK_l_-G3MsmpyMxOh6fvCT3rcX1IvZIZzFfmleIqRbqdfPO_AEjPRzt |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lower+HCV+treatment+uptake+in+women+who+have+received+opioid+agonist+therapy+before+and+during+the+DAA+era%3A+The+ANRS+FANTASIO+project&rft.jtitle=The+International+journal+of+drug+policy&rft.au=Rojas+Rojas%2C+Teresa&rft.au=Di+Beo%2C+Vincent&rft.au=Delorme%2C+Jessica&rft.au=Barre%2C+Tangui&rft.date=2019-10-01&rft.eissn=1873-4758&rft.volume=72&rft.spage=61&rft_id=info:doi/10.1016%2Fj.drugpo.2019.05.013&rft_id=info%3Apmid%2F31129024&rft.externalDocID=31129024 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0955-3959&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0955-3959&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0955-3959&client=summon |